XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases Sep 12, 2007 8:05am EDT
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director Aug 06, 2007 8:15am EDT
XOMA to Present At Canaccord Adams Global Growth Conference On August 9, 2007 Aug 02, 2007 9:00am EDT
XOMA Announces August 8 Conference Call and Webcast Discussion of Second Quarter 2007 Financial Results Aug 01, 2007 9:00am EDT
XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory Diseases Jul 16, 2007 8:35am EDT
